Lundbeck to Present a Breadth of Migraine and Cluster Headache Data at the 66th Annual Scientific Meeting of the American Headache Society
Otsuka, Lundbeck start ad push for long-acting bipolar drug
After the FDA forced Rexulti depression ads off the air, Lundbeck reported a flattening of prescriptions that is rebounding now promotion has resumed.
Otsuka and Lundbeck’s atypical antipsychotic Rexulti has taken the crown away from AbbVie as the largest TV drug ad spender in April, according to the latest data out from real-time ad trackers iSpot.TV.
Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease
Lundbeck’s Charl van Zyl has about 100 days under his belt as the company’s new CEO. For the next 100 days and beyond, the chief exec is buckling down on his efforts to sustain the company's growth trajectory through upcoming patent cliffs.
Lundbeck is taking a new tack in its migraine marketing for Vyepti, the only IV-infused option in the crowded market. The campaign, launched this week, reinforces the brand name with a “Say Yep” reminder and not having to worry about daily migraine management.
Lundbeck and Otsuka have adopted a soft tone for their first branded ad for Rexulti in dementia-related agitation, replacing the violence and discordance of their earlier awareness spot with a focus on how much children continue to love their parents as they start to lose them to Alzheimer’s disease.
Enforcement Report - Week of September 6, 2023